Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SpectRx cervical cancer test

This article was originally published in The Gray Sheet

Executive Summary

Subsidiary Guided Therapeutics' pre-pivotal clinical trial demonstrates 95% sensitivity. Funded with a $1.4 mil. grant from the National Cancer Institute, the 506-patient, four-site study correctly identified 18 cases of high-grade pre-cancer found to be normal or ambiguous with a regular Pap smear - an 18% increase in detection. The non-invasive test, which identifies cancer by analyzing light reflected from the cervix, may cut unnecessary follow-up procedures from false-positive Pap tests by 55% and could save $181 mil. in U.S. health costs annually, the firm says...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT019658

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel